vs

Side-by-side financial comparison of Atour Lifestyle Holdings Ltd (ATAT) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

Atour Lifestyle Holdings Ltd is the larger business by last-quarter revenue ($789.6M vs $406.6M, roughly 1.9× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 17.6%, a 42.9% gap on every dollar of revenue. On growth, Atour Lifestyle Holdings Ltd posted the faster year-over-year revenue change (252.5% vs 209.1%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $210.7M).

Atour Lifestyle Holdings Ltd is a leading China-based hospitality and lifestyle enterprise. It operates a wide portfolio of mid-to-premium hotel brands for business and leisure travelers, and offers complementary lifestyle retail products and experience services, catering primarily to middle-class consumers across domestic and selected overseas markets.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

ATAT vs BCRX — Head-to-Head

Bigger by revenue
ATAT
ATAT
1.9× larger
ATAT
$789.6M
$406.6M
BCRX
Growing faster (revenue YoY)
ATAT
ATAT
+43.5% gap
ATAT
252.5%
209.1%
BCRX
Higher net margin
BCRX
BCRX
42.9% more per $
BCRX
60.5%
17.6%
ATAT
More free cash flow
BCRX
BCRX
$80.5M more FCF
BCRX
$291.2M
$210.7M
ATAT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ATAT
ATAT
BCRX
BCRX
Revenue
$789.6M
$406.6M
Net Profit
$139.1M
$245.8M
Gross Margin
97.7%
Operating Margin
22.5%
64.0%
Net Margin
17.6%
60.5%
Revenue YoY
252.5%
209.1%
Net Profit YoY
322.2%
1017.5%
EPS (diluted)
$0.33
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATAT
ATAT
BCRX
BCRX
Q4 25
$406.6M
Q3 25
$789.6M
$159.4M
Q2 25
$163.4M
Q1 25
$145.5M
Q4 24
$131.5M
Q3 24
$224.0M
$117.1M
Q2 24
$109.3M
Q1 24
$203.4M
$92.8M
Net Profit
ATAT
ATAT
BCRX
BCRX
Q4 25
$245.8M
Q3 25
$139.1M
$12.9M
Q2 25
$5.1M
Q1 25
$32.0K
Q4 24
$-26.8M
Q3 24
$33.0M
$-14.0M
Q2 24
$-12.7M
Q1 24
$35.6M
$-35.4M
Gross Margin
ATAT
ATAT
BCRX
BCRX
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
ATAT
ATAT
BCRX
BCRX
Q4 25
64.0%
Q3 25
22.5%
18.6%
Q2 25
18.2%
Q1 25
14.6%
Q4 24
-3.4%
Q3 24
14.7%
6.6%
Q2 24
8.0%
Q1 24
22.1%
-15.6%
Net Margin
ATAT
ATAT
BCRX
BCRX
Q4 25
60.5%
Q3 25
17.6%
8.1%
Q2 25
3.1%
Q1 25
0.0%
Q4 24
-20.4%
Q3 24
14.7%
-12.0%
Q2 24
-11.6%
Q1 24
17.5%
-38.1%
EPS (diluted)
ATAT
ATAT
BCRX
BCRX
Q4 25
$1.13
Q3 25
$0.33
$0.06
Q2 25
$0.02
Q1 25
$0.00
Q4 24
$-0.13
Q3 24
$0.08
$-0.07
Q2 24
$-0.06
Q1 24
$0.09
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATAT
ATAT
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$669.2M
$274.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$405.0M
$-119.2M
Total Assets
$1.1B
$514.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATAT
ATAT
BCRX
BCRX
Q4 25
$274.7M
Q3 25
$669.2M
$212.9M
Q2 25
$260.0M
Q1 25
$295.1M
Q4 24
$320.9M
Q3 24
$506.0M
$96.8M
Q2 24
$78.4M
Q1 24
$520.7M
$84.3M
Total Debt
ATAT
ATAT
BCRX
BCRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$277.0K
Stockholders' Equity
ATAT
ATAT
BCRX
BCRX
Q4 25
$-119.2M
Q3 25
$405.0M
$-387.9M
Q2 25
$-421.6M
Q1 25
$-451.9M
Q4 24
$-475.9M
Q3 24
$291.3M
$-468.6M
Q2 24
$-475.6M
Q1 24
$323.5M
$-476.2M
Total Assets
ATAT
ATAT
BCRX
BCRX
Q4 25
$514.2M
Q3 25
$1.1B
$446.4M
Q2 25
$457.2M
Q1 25
$480.0M
Q4 24
$490.4M
Q3 24
$927.8M
$491.3M
Q2 24
$472.4M
Q1 24
$936.3M
$467.9M
Debt / Equity
ATAT
ATAT
BCRX
BCRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATAT
ATAT
BCRX
BCRX
Operating Cash FlowLast quarter
$216.6M
$292.0M
Free Cash FlowOCF − Capex
$210.7M
$291.2M
FCF MarginFCF / Revenue
26.7%
71.6%
Capex IntensityCapex / Revenue
0.8%
0.2%
Cash ConversionOCF / Net Profit
1.56×
1.19×
TTM Free Cash FlowTrailing 4 quarters
$359.6M
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATAT
ATAT
BCRX
BCRX
Q4 25
$292.0M
Q3 25
$216.6M
$41.6M
Q2 25
$41.3M
Q1 25
$-27.5M
Q4 24
$-5.2M
Q3 24
$84.8M
$8.2M
Q2 24
$-1.4M
Q1 24
$19.8M
$-53.7M
Free Cash Flow
ATAT
ATAT
BCRX
BCRX
Q4 25
$291.2M
Q3 25
$210.7M
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$83.3M
$8.2M
Q2 24
$-1.5M
Q1 24
$18.1M
$-53.9M
FCF Margin
ATAT
ATAT
BCRX
BCRX
Q4 25
71.6%
Q3 25
26.7%
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
37.2%
7.0%
Q2 24
-1.4%
Q1 24
8.9%
-58.1%
Capex Intensity
ATAT
ATAT
BCRX
BCRX
Q4 25
0.2%
Q3 25
0.8%
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.7%
0.1%
Q2 24
0.1%
Q1 24
0.9%
0.3%
Cash Conversion
ATAT
ATAT
BCRX
BCRX
Q4 25
1.19×
Q3 25
1.56×
3.23×
Q2 25
8.12×
Q1 25
-859.91×
Q4 24
Q3 24
2.57×
Q2 24
Q1 24
0.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons